^
    Back
    Association details:
    Biomarker:MYD88 L265P
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Polivy (polatuzumab vedotin-piiq) + Rituxan (rituximab) + Brukinsa (zanubrutinib))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    1747 Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

    Published date:
    11/02/2023
    Excerpt:
    Six (75%) patients had MYD88 L265P mutation in 8 patients with sequencing results. After a median follow up of 2.1 months, four patients had PET/CT assessment results after 3 cycles of ZPR, and four (100%) of them achieved CR. The ORR after 3 cycles of ZPR regimen was 100% (Figure 2)...Based on these results in our study, ZPR regimen showed rapid and deep response in previously untreated frail and elderly DLBCL patients with manageable safety profiles.